Retrophin, Inc. RTRX today announced that it has signed an
agreement with Novartis Pharma AG NVS for an exclusive U.S. license for
Syntocinon™ Nasal Spray, the intranasal formulation of a synthetic
version of the naturally occurring peptide hormone oxytocin, for an
upfront payment of $5.0 million plus milestone payments and royalties.
Syntocinon™ Nasal Spray was approved in the U.S. in 1960 to assist
initial postpartum milk ejection, but was discontinued by Novartis in
1997 for commercial reasons. Retrophin plans to reintroduce the product
for prescription use in the U.S. in Q2 2014. Additionally, the company
intends to pursue a clinical trial program with Syntocinon™ for its
potential use as a treatment for schizophrenia and autism.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in